Arcus Biosciences Inc RCUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RCUS is a good fit for your portfolio.
News
-
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
-
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Trading Information
- Previous Close Price
- $14.98
- Day Range
- $15.08–15.91
- 52-Week Range
- $12.95–25.47
- Bid/Ask
- $15.39 / $16.84
- Market Cap
- $1.44 Bil
- Volume/Avg
- 433,942 / 703,324
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 577
- Website
- https://www.arcusbio.com
Comparables
Valuation
|
Metric
|
RCUS
|
PRLD
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.03 | 1.51 | 4.09 |
Price/Sales | 5.16 | — | 298.58 |
Price/Cash Flow | — | — | — |
Price/Earnings
RCUS
PRLD
IGMS
Financial Strength
|
Metric
|
RCUS
|
PRLD
|
IGMS
|
|---|---|---|---|
Quick Ratio | 5.07 | 11.44 | 7.75 |
Current Ratio | 5.22 | 11.64 | 7.98 |
Interest Coverage | −135.00 | — | — |
Quick Ratio
RCUS
PRLD
IGMS
Profitability
|
Metric
|
RCUS
|
PRLD
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −12.95% | −39.87% | −45.69% |
Return on Equity (Normalized) | −27.45% | −44.79% | −90.75% |
Return on Invested Capital (Normalized) | −33.04% | −43.35% | −81.91% |
Return on Assets
RCUS
PRLD
IGMS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Vfvhfhlyvc | Lbjph | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tlczwpzwr | Tvlksnm | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ghtmqyh | Zljggc | $118.7 Bil | |||
| Moderna Inc
MRNA
| Nqbzyyk | Ncryv | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Smwdfrbl | Ctwdyg | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Fnrtfpj | Xsbr | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Xhdcmyrl | Blxzw | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hnkprlxw | Fdwwbcv | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tnqddqhg | Txh | $15.0 Bil | |||
| Incyte Corp
INCY
| Brzwyvrm | Crzzsh | $13.5 Bil |